TapImmune announces results from HER2/neu interim study on breast cancer
 

TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.

More...

Re: TapImmune announces results from HER2/neu interim study on breast cancer
 

I was just about to post the link to this article but I see it is already here. I have been following this study. This seems like great progress, but oh, how I wish these trials could go faster! One step closer, I guess!